Immuneering price target lowered to $12 from $13 at Piper Sandler

Piper Sandler lowered the firm’s price target on Immuneering (IMRX) to $12 from $13 and keeps an Overweight rating on the shares following the company’s Q4 update. Timing for near-term clinical catalysts is tracking as expected, with updated ctDNA and expanded Phase 2a survival data in first line PDAC guided to Q2 and first half of 2026, respectively, with dosing of the first patient in the pivotal MAPKeeper 301 study planned for mid-2026.